Aarti Drugs Ltd Secures Favorable Supreme Court Ruling in ₹230 Crore Tax Dispute

Aarti Drugs Ltd has successfully concluded a significant tax dispute, with the Supreme Court dismissing a petition filed by the GST Department.

Reader Takeaway: Supreme Court victory for Aarti Drugs; ₹230.70 crore tax dispute fully resolved positively.

What Just Happened

The Supreme Court has dismissed a Special Leave Petition (SLP) filed by the GST Department, effectively ending a tax dispute concerning alleged contravention of Rule 96(10) of the CGST Rules. The original show cause notice had sought a total demand of ₹230.70 crore for the period between FY 2017-18 and FY 2021-22.

Why This Matters

This ruling provides finality to a substantial legal and financial matter for Aarti Drugs. The dismissal of the GST Department's petition means the company is no longer liable for the contested amounts, removing a significant overhang and offering greater financial certainty.

The Backstory

The dispute originated from an IGST demand notice. While a portion of the demand (₹209.98 crore) was initially dropped by authorities, a refund demand of ₹20.72 crore and a penalty of ₹20.72 crore were contested. Aarti Drugs had previously won a favorable order from the High Court of Judicature at Bombay, which the GST Department then appealed to the Supreme Court.

What Changes Now

With the Supreme Court's decision, the matter is now disposed of in favor of Aarti Drugs. The company has confirmed that this resolution has no impact on its financial, operational, or other activities, indicating its operations were not constrained by this pending litigation.

Risks to Watch

There are no new risks arising from this specific filing. The successful resolution mitigates the risk associated with the ₹230.70 crore tax demand.

Peer Comparison

Tax disputes are common in the Indian corporate landscape, especially post-GST implementation. Companies often engage in litigation to contest demands related to tax interpretation and compliance. Aarti Drugs' successful navigation of this dispute up to the Supreme Court highlights robust legal defense capabilities.

Context Metrics (Time-Bound)

• Dispute Subject: Alleged contravention of Rule 96(10) of CGST Rule.
• Original Demand (SCN): ₹230.70 Crore.
• Period of Dispute: FY 2017-18 to FY 2021-22.
• Supreme Court Outcome: SLP dismissed.
• Final Status: Matter disposed of in favor of Aarti Drugs Ltd.

What to Track Next

Investors can monitor Aarti Drugs' future financial statements for any minor adjustments if previously provisioned, though the company states no impact. The primary focus will now shift to the company's core business performance and growth strategies.